| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-493-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB293-SP | |||
| Carrier Free | MAB293-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-664SS | |||
| Azide and BSA Free | NBP2-81007 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-293-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF564-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-648SS | |||
| Azide and BSA Free | NBP2-81006 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB3045-SP | |||
| Carrier Free | MAB3045-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-20875 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-21068 | |||
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib reduced TNBC cell migration & targeted p-STAT3/VEGF-A signaling.(A) Chemical structure of regorafenib. (B,C), Transwell assay (B) & wound-healing assay (C) were performed in TNBC cell lines after regorafenib treatment for 24 h. *p 160) or low VEGF-A (H score < = 160) levels for the indicated time of follow up. Chi-square test indicated a significant difference between VEGF-A high (N = 21) & low (N = 76) patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-3102024155374.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-31020241682159.jpg)
![Analysis of a FFPE tissue section of human liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-664_mouse-monoclonal-vegf-antibody-vg1-immunohistochemistry-paraffin-1211202510571.jpg)
![Analysis of a FFPE tissue section of mouse liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-664_mouse-monoclonal-vegf-antibody-vg1-immunohistochemistry-paraffin-12112025105832.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0004.jpg "Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.")
![Western Blot: VEGF Antibody (VG76e) [NB100-648] - Analysis of VEGF in human kidney protein (30ug).](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Western-Blot-NB100-648-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: VEGF Antibody (VG76e) [NB100-648] - Immunofluorescent analysis of VEGF using NB100-648. This image submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunocytochemistry-Immunofluorescence-NB100-648-img0007.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC-P analysis of VEGF in sheep tonsil using NB100-648. This image was submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0006.jpg)
![Western Blot: Mouse Monoclonal VEGF Antibody (VG76e) [NB100-648] - Bone lysate homogenate from goats. SDS-PAGE with 0.3 mg of total protein from the homogenate per well. VEGF, NB100-648, was used at a dilution of 1:1000 in TBS Tween and 5% milk powder. The protein was labeled at 40 kDa. Quantification of VEGFA in bone graft in the tibia of intrailiac cellularized goats at different times compared with tibial autograft and untreated bone defect. Evaluation of pre-cellularized graft in iliac crest in the treatment of bone defects in the tibia of goats. G1: cellularized graft for 4 weeks applied to tibial bone defect, G2: cellularized graft for 6 weeks applied to tibial bone defect, G3: cellularized graft for 8 weeks applied to tibial bone defect, G4: tibial autograft and G5: untreated bone defect. All groups were evaluated 120 days after graft implantation. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-648_mouse-monoclonal-vegf-antibody-vg76e-western-blot-2952025142053..jpg)
